Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

#3525

Introduction: SPINET (NCT02683941) evaluated lanreotide autogel/depot (LAN) in metastatic somatostatin receptor (SSTR)-positive typical and atypical (TC and AC) BP NETs.

Aim(s): To perform exploratory analyses assessing prognostic factors for PFS.

Materials and methods: A phase 3, randomized, double blind (DB), placebo (PBO)-controlled study of LAN (120 mg/28 days), with optional open-label LAN treatment phase (OL LAN). Enrollment was stopped due to slow accrual (recruitment, Jul 2016–Aug 2018; planned sample size, 216). A post hoc Cox proportional hazards model was used to evaluate prognostic factors for PFS during the DB phase. Treatment, prior chemotherapy, tumor subtype, age, body mass index and time since diagnosis were included in the univariate analysis; those with a p-value <0.2 were included in the multivariate analyses.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, prognostic factor, spinet, typical/atypical carcinoid,